Pharmacodynamics (Exam 1) Flashcards
Agonist
Activator
Antagonist
Inhibitor
Endogenous
Naturally made
Xenobiotics
Synthetically made
Drug Targets
- Receptors
- Enzymes
- Ion Channels
- Transports/Carriers/Pumps
Types of Receptors
Ligand-Gated Ion Channels (LGIC)
G-Protein Coupled Receptors (GPCR)
Enzyme-Linked Receptors
Intracellular Receptors
Affinity
Strength of attraction between drug and its binding site
Covalent
Strong and in many cases not reversible
Least Common
Electrostatic
Vary from relatively strong linkages to weaker hydrogen bonds to van der Waals
Most Common
Hydrophobic
Important for highly lipid soluble drugs
Drug Response
Result of chemical interactions between a drug and binding site
Receptors
Transmembrane proteins located within cell membrane
How do receptors work?
Bind to ligand and propagate a signal leading to effect/response
Ligand
Molecule which produces a signal by binding to a site on receptor
Receptor Mediated Messenger System
First Messenger - ligand
Signal Transducer - receptors
Effector - enzymes activated by signal transduction
Second Messenger - Signaling molecules that activate other targets, allows for signal amplification
Autocrine Signaling
Ligand originates from same cell
Autoreceptor
Receptors whose purpose is to bind their own ligand as negative feedback mechanism
Paracrine Signaling
Ligand originates from nearby cell
Endocrine Signaling
Ligand originates from distant cell and travels through bloodstream
Hormones
Ligands of endocrine system
Ligand Gated Ion Channels (LGIC)
Ligand binding causes conformational change that opens channel allowing ions (Na+, Ca2+, K+, Cl-) to pass through
LGIC for Na+ and Ca2+
Excitatory
Make cell more positive, closer to threshold potential
LGIC for Cl- and K+
Inhibitory
Make cell more negative, farther from threshold potential
Acetylcholine (LGIC)
Nicotinic Receptor
LGIC (Na+)
Serotonin (LGIC)
5HT3 Receptor
LGIC (Na+)
Glutamate (LGIC)
NMDAR Receptor –> LGIC (Ca2+)
AMPAR Receptor –> LGIC (Na+)
GABA (LGIC)
GABA-A Receptor
LGIC (Cl-)
G-Protein Coupled Receptors (GPCRs)
Receptor bound to G-protein and leads to G-protein activation
Gs GPCRs
Activates adenylyl cyclase (AC)
Gi GPCRs
Inhibits adenylyl cyclase (AC)
Gq GPCRs
Activates phospholipase C (PLC)
What determines if receptor is Gs, Gi, or Gq?
The alpha subunit of G-protein
Gs Signaling Pathway
AC is activated and converts ATP to cAMP
cAMP acts as second messenger –> activates cAMP dependent protein kinases
Kinases phosphorylate other proteins
Gi Signaling Pathway
AC is inhibited
Sometimes K+ channels opened
Gq Signaling Pathway
Phospholipase C (PLC) is activated and converts PIP2 into DAG and IP3
DAG and IP3 act as second messengers
DAG activates PKC which activates other enzymes
IP3 causes Ca2+ release from intracellular storage
Ca2+ activates calmodulin –> other enzymes
Acetylcholine (GPCR)
M1, M3, M5 Receptor –> GPCR Gq
M2, M4 Receptor –> GPCR Gi
Norepinephrine/Epinephrine (GPCR)
alpha-1 receptor –> GPCR Gq
alpha-2 receptor –> GPCR Gi
beta1-3 receptor —> GPCR Gs
Dopamine (GPCR)
D1, D5 Receptor –> GPCR Gs
D2, D3, D4 Receptor –> GPCR Gi
Serotonin (GPCR)
5HT1, 5 Receptor –> GPCR Gi
5HT2 Receptor –> GPCR Gq
5HT4, 6, 7 Receptor –> GPCR Gs
Endogenous cannabinoids (GPCR)
CB1, CB2 Receptor –> GPCR G1
Endogenous opioids (GPCR)
Mu, delta, kappa Receptors –> GPCR Gi
Which receptor works quicker? GPCR or LGIC
LGIC because there’s no second messenger system
Activation of which receptor leads to increase in cAMP?
Gs coupled receptors
Enzyme-Linked Receptors
Linked to an enzyme that mediates downstream signaling
Alter gene expression to produce effects –> slow onset and long duration
Receptor Tyrosine Kinases
Enzyme within receptor
Ligand binds to receptor –> Conformational change leads to dimerization –> Activates tyrosine kinase function –> phosphorylation of tyrosine residue -> receptor becomes activated and phosphorylates downstream proteins
Which ligand uses receptor tyrosine kinases?
Insulin
Cytokine receptors
Enzyme as separate protein
Enzyme binds non-covalently and becomes activated following ligand binding and dimerization
Which ligand uses cytokine receptors?
Growth hormone
Intracellular/Nuclear Receptors
Ligand must be lipid soluble to cross cell membrane
Nuclear receptors bind to DNA and regulate gene expression
Contain ligand binding domain (LBD) and DNA binding domain (DBD)
Type 1 Nuclear Receptors
In cytosol but enter nucleus after ligand binding
Type 2 Nuclear Receptors
Remain in nucleus and ligand must enter to bind
Which ligands use Type 1 Nuclear Receptors?
Sex hormones and glucocorticoids
Which ligands use Type 2 Nuclear Receptors?
Vitamin D and thyroid hormone
Onset and Duration of LGIC
Onset: Milliseconds
Duration: Seconds
Onset and Duration of GPCR
Onset: seconds to minutes
Duration: minutes to hours
Onset and Duration of Kinase-Linked Receptors
Onset: 30 mins to an hour
Duration: Hours to days
Onset and Duration of Nuclear Receptors
Onset: 30 mins to hours
Duration: Hours to days
Regulation of Recepetors
Overstimulated receptor leads to decreasing sensitivity or number of receptors
Can occur due to high levels of endogenous ligand or drug
Competitive inhibitor
Bind to enzyme at same site as substrate
Noncompetitive inhibitor
Bind to enzyme at different site and block reaction from occurring
Uncompetitive inhibitor
Bind only to enzyme-substrate complex and block reaction form occurring
Intracellular Enzyme
Phosphodiesterase (PDE) - responsible for breaking down cAMP and cGMP
What is an example of competitive inhibitor of PDE5?
Sildenafil
Used to treat ED and pulmonary arterial hypertension
Extracellular Enzyme
Acetylcholinesterase (AChE) - responsible for breaking down acetylcholine in synapse
What is an example of competitive inhibitor of AChE?
Donepezil
Treatment of Alzheimer’s disease
Voltage Gated Ion Channels (VGICs)
Change in voltage causes conformational change that opens channel and allows ions to pass through
Rapid Signaling
VGIC fo Na+ or Ca2+
Excitatory
More positive cell and closer to threshold potential
VGIC for Cl- or K+
Inhibitory
More negative cell and farther from threshold potential
Ca2+ VGIC in Vasculature
Blocked by some blood pressure lowering drugs
Na+ VGIC on Neurons
Blocked by some drugs used to treat epilepsy
Transporters/Pumps/Carriers
Proteins that help bring small molecules across biological membranes
Why are transporters different than channels?
Transporters have binding sites for transported molecules
Channels are simultaneously open to inner and outer membrane
Serotonin Transporter
Uptake of serotonin from synapse into presynaptic neuron
(SSRIs) block transporter and increase serotonin levels in synapse
A drug binds to receptor located in the cytosol. Then, the drug-receptor complex travels to nucleus and enhances transcription. What kind of receptor is this?
Nuclear Receptor
Drug Receptor Theory
Formation of drug-receptor complex leads to biological response
Assumptions of Drug Receptor Theory
Reversible manner
Increase in drug concentration increase response, visa versa
Max response achieved when receptors saturated
Drugs competing with endogenous ligand
What receptor does norepinephrine activate?
Beta1 receptors on the heart leading to increase in heart rate
What receptor does acetylcholine activate?
M2 receptors in the heart leading to a decrease in heart rate
Full agonist
Produces same maximum response as endogenous ligand
Partial agonist
Produces lower maximum response than endogenous ligand
A partial agonist acts as net agonists when…
…endogenous ligand concentrations are low
A partial agonist acts as net antagonists when…
…endogenous ligand concentrations are high
Competitive antagonist
Competes with endogenous ligand for binding site
Non-competitive antagonist
Does not compete with endogenous ligand
Binds to allosteric site
Reversible Antagonist
Binds reversibly to the receptor
Irreversible Antagonist
Binds covalently to the receptor
Inverse agonist
Reduces receptor activity below basal levels
Decrease constitutive activity
Constitutive (Basal) Activity
Low levels of basal activity, even when there is no ligand present
Positive Allosteric Modulators (PAM)
Bind to receptor at allosteric site and either increase receptor affinity OR increase receptor efficacy
Negative Allosteric Modulators (NAM)
Bind to receptor at allosteric site and either decrease receptor affinity OR decrease receptor efficacy
An ion channel has constitutive activity of 5 Ca2+ ions per second. The endogenous ligand for an ion channel causes the influx of 20 Ca2+ per second. If drug A binds to ion channel and cause the influx of 2 Ca2+ per second, what best describes drug A?
Inverse agonist
Dose-response curve
Describes relationship between the dose/concentration of drug molecule and specific effect/response
Efficacy
Measure of the maximum biological response produced by the drug
Intrinsic Activity (IA)
Drug’s maximal efficacy as a fraction of maximal efficacy produced by endogenous ligand
Saturation Binding Curve
Drug concentration versus number/percentage of receptors bound
Determine affinity
Key parameters of saturation binding curve
Bmax and KD
Dose Response Curve
Drug concentration/dose versus effect/response
Determine efficacy and potency
Key parameters of dose response curve
Emax and EC50
Bmax
Concentration of receptor sites (total number of receptors)
KD
Drug concentration at which 50% of receptors are bound
Relationship between KD and affinity
Smaller KD will have a higher binding affinity
Inversely proportional
Emax
Maximum possible response that a drug can produce
Relationship between Emax and Efficacy
Larger Emax will have higher efficacy
Directly proportional
EC50/ED50
Amount of drug needed to produce 50% of the maximum response
Relationship between EC50 and Potency
Smaller EC50 will have higher potency
Inversely proportional
Relationship between slope and sensitivity
Steeper slope means higher sensitivity
A shift to the right of dose response curve means…
…competitive antagonist
A downward shift of the dose response curve means…
….non-competitive or irreversible antagonist
Changning Emax
Spare receptor
When possible to elicit a maximal response at a concentration of agonist that does not result in occupancy of all available receptors
Reasons for Spare Receptors
- Number of receptors may be greater than number of available downstream signaling molecules
- Duration of activation of signaling molecules is much greater than duration of drug-receptor interaction
Selectivity
Degree to which drug acts on a specific tissue or target relative to others
Tissue Selectivity
When receptor or target is only found in one type of tissue
Direct application may provide some selectivity
Target Selectivity
Antibody drugs usually have high selectivity for target
Temporal relationship between drug binding and effect
Drug remains bound: persistent effect until complex is destroyed or new molecules produced
Drug dissociates from target:
Terminate drug action, may persist due ti coupling molecule being active
Idiosyncratic
Rare and unpredictable drug response
Hyporeactive
Patients who have lower degree of drug response
Hyperreactive
Patients who have higher degree of drug response
Tolerance
Diminishing drug efficacy over time
Tachyphylaxis
Tolerance that occurs rapidly after use of a drug
Quantal Dose-Response Curve
Dose of drug versus percentage of individuals experiencing specific effect
Therapeutic Index (TI)
Relationship between dose of drug that causes toxicity versus the dose that causes therapeutic effects
TI = TD50 / ED50
Which of the following drugs would be considered the safest, based on therapeutic index?
Drug with TD50 of 20mg and ED50 of 1mg
20 / 1 = 20
Therapeutic Window
Dose or concentration range which can treat disease effectively without having toxic effects
Larger the therapeutic window the safer the drug
Therapeutic Drug Monitoring
Plasma concentrations are monitored to ensure serum concentrations within therapeutic window